SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid fears of Middle East supply disruptions, especially attacks and threats affecting shipping around the Strait of Hormuz, alongside risks to oil infrastructure. Traders are split between viewing the supply concerns as support for further gains and expecting a pullback if tensions ease or the rally fades.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStops warrants nearing expiration, with the shares below the exercise price and holders debating whether the warrants will expire worthless. Bears criticize Cohen and doubt an extension or catalyst will arrive, while bulls speculate he may take action; some also view unused warrants as avoiding dilution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound in the Nasdaq has sparked volatile trading, with traders debating whether the sharp bounce can hold or is a bull trap. AI infrastructure spending and debt concerns, rising oil prices, and upcoming megacap earnings are keeping sentiment divided.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and higher-rate concerns have weighed on rate-sensitive small caps, with traders highlighting IWMs technical weakness and heavy demand for puts. The community is split between expecting an oversold bounce or rotation into small caps and anticipating further declines if support fails.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing the analyst price-target cut, IPO lockup share releases and concerns about insider selling, alongside broader weakness in AI hardware. Bulls see an oversold opportunity and point to its wafer-scale technology, while bears question its valuation, ability to scale and reliance on OpenAI.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas equity offering to fund expansion has been a major focus, with traders debating the dilution and the sharp, volatile pullback it accompanied. That concern contrasts with bullish views that AI data-center and networking demand, raised guidance, and expected earnings growth support buying the dip.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its upcoming earnings report, as traders weigh the results and guidance against a sharp pullback in semiconductor equipment stocks. Some see the dip as oversold and are looking for a support bounce, while others remain cautious about further selling and earnings volatility.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

HPE is drawing attention after a sharp selloff alongside enterprise hardware peers, with traders pointing to Barclays downgrade and concerns that AI spending has not yet produced a meaningful growth inflection, while higher memory costs may also temper upside. The community is split between viewing the drop as an overreaction and buying opportunity and worrying that the stock may remain under pressure.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms weak share performance is drawing attention amid a broader semiconductor selloff and concerns about AI spending, financing, and returns; many traders also say CEO Hock Tans casino remarks worsened sentiment. The 10-year NTT DOCOMO VMware agreement is cited as positive news, but traders disagree on whether the deal or strong AI-growth expectations can offset the sector and valuation concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings report is the main focus, with traders watching for guidance on growth, subscriber engagement and advertising amid recent content-leadership changes and layoffs. The discussion is split between bearish concern about slowing growth and the stocks recent weakness, and bullish hopes that subdued expectations could leave room for a positive reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual...

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30...

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. $UPC, $NTHI, $DCOY, $VRDN

Futures Rise As Dip-Buyers Lift Tech Stocks

Futures Rise As Dip-Buyers Lift Tech Stocks

 US equity futures are higher led by Tech as Mag7 leads the group higher and points to a reversal of last week's profit-taking, as traders position for the end of the first half. A shortened week will likely focus on a speech from the Fed's...

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.read more...

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval  

Equity

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 


Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze...

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</li><li>Physicians can begin prescribing Lumvoa immediately, the company said.</li><li>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems.</li></ul><p>Shares of Viridian Therapeutics Inc (VRDN) jumped 6% after-hours on Friday after the U.S. Food and Drug Administration approved its drug Lumvoa for the treatment of thyroid eye disease.</p><p>The drug is now available by prescription and marks the company’s first approved medicine and first commercial product.</p><h2 class="st-heading-2">New Option For Active And Chronic Disease</h2><p>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems. Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</p><h2 class="st-heading-2">Strong Results In Key Trials</h2><p>The approval was based on two large late-stage studies — THRIVE in active TED and THRIVE-2 in chronic TED. In both trials, Lumvoa met all primary and secondary goals. Patients saw rapid reductions in eye bulging and double vision, with improvements beginning as early as three weeks. The drug is given as five intravenous infusions over 12 weeks.</p><h2 class="st-heading-2">Immediate Launch And Patient Support</h2><p>Physicians can begin prescribing Lumvoa immediately, the company said. Viridian has launched ViridianCares, a patient support program that offers insurance navigation, financial assistance, and dedicated support staff to help eligible patients access treatment.</p><h2 class="st-heading-2">Company And Expert Reaction</h2><p>“This approval represents a major step forward for people living with thyroid eye disease,” said Steve Mahoney, President and CEO of Viridian. “Lumvoa was designed with patients in mind and addresses a clear need across the full spectrum of the disease.”</p><p>In addition to Lumvoa, Viridian is advancing VRDN-003, a subcutaneous anti-IGF-1R antibody designed for self-administration via autoinjector. The company recently reported positive topline results from two pivotal late-stage trials in active and chronic thyroid eye disease.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRDN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p>A Stocktwits user cheered the news as “massive” and recommended watching the stock next week.</p><p><stembedurl>https://www.stocktwits.com/Daniel_2025/message/657668888</stembedurl></p><p>According to data from Koyfin, 16 of the 17 analysts covering VRDN stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $33.94, representing a potential upside of about 90% from the last closing price.</p><p><a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 42% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/upc-stock-surges-after-hours-whats-driving-the-rally/cZ12TA7R7WB">UPC Stock Surges 288% After Hours — What’s Driving The Rally?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Viridian Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$20.80
Prev Close	$19.03
Open	$19.23
Dividend Yield	0.00%
50-Day Moving Average	$21.61
Beta	1.14
Avg. Volume	1.68M
PE Ratio	-5.61

52-Week High	$34.29
52-Week Low	$13.18
Market Capitalization	$2.16B
EPS (Annual)	-$3.32
Price to Book	4.18
Revenue Per Employee	$281,146.83

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRDN Fundamentals